Sunday
2:00 pm - 9:00 pm
Arrival and Check-in
6:00 pm - 7:00 pm
Dinner
7:30 pm - 7:40 pm
Introductory Comments by GRC Staff / Welcome and Introduction from the Chairs
7:40 pm - 9:30 pm
Keynote Session: Exploring the Power of Radioimmunobiology Via Switching the Radionuclides, Ligands and Immunotargets
7:40 pm - 8:00 pm
"Terbium-161 for the Next-Generation Novel Radiopharmaceuticals"
8:00 pm - 8:15 pm
Discussion
8:15 pm - 8:35 pm
"30 Years Ago: The Dawn of Radiometal Theranostics"
8:35 pm - 8:50 pm
Discussion
8:50 pm - 9:15 pm
"The Radionuclide Portfolio for Theranostics"
9:15 pm - 9:30 pm
Discussion
Monday
7:30 am - 8:30 am
Breakfast
9:00 am - 12:30 pm
Clinical Trial Updates in Radionuclide Theranostics
9:00 am - 9:25 am
"Reimagining Radiopharmaceuticals: Lessons Learned and Future Outlook"
9:25 am - 9:40 am
Discussion
9:40 am - 10:05 am
"Clinical Update: Targeted Copper Theranostics in Prostate Cancer"
10:05 am - 10:20 am
Discussion
10:20 am - 10:50 am
Coffee Break
10:50 am - 11:15 am
"Scientific Frontiers in Targeted Alpha Therapy: ACTION-1 and Beyond"
11:15 am - 11:30 am
Discussion
11:30 am - 11:55 am
"Targeted Radiolabeled Nanoliposomes for Rare CNS Cancers: An Update on the ReSPECT Phase 1/2 Trials"
11:55 am - 12:10 pm
Discussion
12:10 pm - 12:30 pm
Poster Previews
12:30 pm - 1:30 pm
Lunch
1:30 pm - 4:00 pm
Free Time
3:00 pm - 4:00 pm
The GRC Power Hour™
The GRC Power Hour™ is designed to address diversity and inclusion in the scientific workplace by providing a safe environment for informal and meaningful conversations amongst colleagues of all career stages. The program supports the professional growth of all members of our communities, including ethnicity, race and/or gender identity by providing an open forum for discussion and mentoring.
4:00 pm - 6:00 pm
Poster Session
6:00 pm - 7:00 pm
Dinner
7:30 pm - 9:30 pm
Radio(immuno)biology: Relative Biological Effectiveness, Dose and Immune System Interaction
7:30 pm - 7:55 pm
"Exploiting the Biological Effects of Therapeutic Radionuclides in Solid Tumours"
7:55 pm - 8:10 pm
Discussion
8:10 pm - 8:35 pm
"Radionuclide Therapy Dose-Effect Relationships: Does the Dose Matter?"
8:35 pm - 8:50 pm
Discussion
8:50 pm - 9:15 pm
"The Discoveries of Auger Electron Processes"
9:15 pm - 9:30 pm
Discussion
Tuesday
7:30 am - 8:30 am
Breakfast
9:00 am - 12:30 pm
Optimization of Targeted Delivery: Pretargeting and Click-Chemistry
9:00 am - 9:25 am
"DOTA Ligand Bound Radionuclide-Based Pretargeted Radioimmunotherapy"
9:25 am - 9:40 am
Discussion
9:40 am - 10:05 am
"Development of Host: Guest Pretargeting for Targeted Radionuclide Therapy"
10:05 am - 10:20 am
Discussion
10:20 am - 10:50 am
Coffee Break
10:50 am - 11:15 am
"Pretargeting with Radiohalogens: From 18F-PET Imaging to 211At-Targeted Radionuclide Therapy"
11:15 am - 11:30 am
Discussion
11:30 am - 11:55 am
"Harnessing Bioorthogonal Click Chemistry for In Vivo Pretargeting"
11:55 am - 12:05 pm
Discussion
12:05 pm - 12:30 pm
Poster Previews
12:30 pm - 1:30 pm
Lunch
1:30 pm - 4:00 pm
Free Time
4:00 pm - 6:00 pm
Poster Session
6:00 pm - 7:00 pm
Dinner
7:30 pm - 9:30 pm
Radiopharmaceutical Therapy Response Biomarkers and Toxicity Screening
7:30 pm - 7:55 pm
"Exploiting Macrophages to Drive Systemic Responses to Radiotherapy: Opportunities for CD47 in Radiopharmaceutical Therapy"
7:55 pm - 8:10 pm
Discussion
8:10 pm - 8:35 pm
"Tumor and Immune-Resistance Mechanisms to PSMA-Targeted Radiopharmaceutical Therapy"
8:35 pm - 8:50 pm
Discussion
8:50 pm - 9:15 pm
"Distinct Radio-Immunobiologic Effects of Radioisotopes and Dose Heterogeneity"
9:15 pm - 9:30 pm
Discussion
Wednesday
7:30 am - 8:30 am
Breakfast
9:00 am - 12:30 pm
Optimization of Targeted Delivery: New Probes and Pro-Drugs
9:00 am - 9:25 am
"Radio-DARPin Therapeutics (RDTs): From Protein Engineering to First Clinical Candidates"
9:25 am - 9:40 am
Discussion
9:40 am - 10:00 am
"Short Peptides (Bicycles) for Optimizing Radionuclide Delivery to Tumors"
10:00 am - 10:15 am
Discussion
10:15 am - 10:45 am
Group Photo / Coffee Break
10:45 am - 11:05 am
"Novel Platform Design for Targeted Alpha-Therapy and Imaging"
11:05 am - 11:20 am
Discussion
11:20 am - 11:40 am
"Advancing Targeted 225Ac Platform: A Peek at What’s Clinically Advancing and What’s to Follow Post Acquisition"
11:40 am - 11:55 am
Discussion
11:55 am - 12:15 pm
"PET/MRI Pilot Studies of All-In-1, Gd-Free, Multimodal, Pretargeted Radiotheranostic Agent as Multikinase Inhibitor"
12:15 pm - 12:30 pm
Discussion
12:30 pm - 1:30 pm
Lunch
1:30 pm - 4:00 pm
Free Time
4:00 pm - 6:00 pm
Poster Session
6:00 pm - 7:00 pm
Dinner
7:30 pm - 9:30 pm
Therapies Radionuclide Supply and Scaling up Manufacturing
7:30 pm - 7:55 pm
"Growing Manufacturing Capacity for Theranostic Radiopharmaceuticals"
7:55 pm - 8:10 pm
Discussion
8:10 pm - 8:35 pm
"PRISMAP: The European Medical Radionuclides Programme, and Scaling-up Stories"
8:35 pm - 8:50 pm
Discussion
8:50 pm - 9:15 pm
"Astatine-211: A Very Convenient Alpha Emitter"
9:15 pm - 9:30 pm
Discussion
Thursday
7:30 am - 8:30 am
Breakfast
8:30 am - 9:00 am
Business Meeting
Nominations for the Next Vice Chair(s); Complete the GRC Evaluation Forms; Election of the Next Vice Chair(s)
9:00 am - 12:30 pm
Overcoming the Barriers in Radiopharmaceuticals
9:00 am - 9:25 am
"Tumor Heterogeneity and Radionuclide Theranostics: Is There a Solution?"
9:25 am - 9:35 am
Discussion
9:35 am - 10:00 am
"Addressing Treatment Response and Tumor Heterogeneity with Large PET/CT Datasets"
10:00 am - 10:10 am
Discussion
10:10 am - 10:40 am
Coffee Break
10:40 am - 11:05 am
"Preclinical In-Vivo Evaluation of SstR2 Agonists and Antagonists Radiolabeled With Various Therapeutic Isotopes"
11:05 am - 11:15 am
Discussion
11:15 am - 11:40 am
"Traversing Serum Decoys: Isoform-Selective Targeting of 4Ig-B7-H3 for PET Imaging and Beta-Radioligand Therapy"
11:40 am - 11:50 am
Discussion
11:50 am - 12:15 pm
"FAP: Beyond Radonuclides and Cancer"
12:15 pm - 12:30 pm
Discussion
12:30 pm - 1:30 pm
Lunch
1:30 pm - 4:00 pm
Free Time
4:00 pm - 6:00 pm
Poster Session
6:00 pm - 7:00 pm
Dinner
7:30 pm - 9:30 pm
Understanding the Cell Death and Toxicity Mechanisms in Response of Radiopharmaceutical Therapy
7:30 pm - 7:55 pm
"Preclinical Optimization of Urinary Kidney Biomarkers to Identify Tolerable Alpha-Radioligand Therapy Dose"
7:55 pm - 8:10 pm
Discussion
8:10 pm - 8:35 pm
"Real Time p53 Tracking to Understand the Cellular Response to Radiation Treatment"
8:35 pm - 8:50 pm
Discussion
8:50 pm - 9:15 pm
"Can We Rethink the RLT Clinical Trial Design for Curative Intent Therapies?"
9:15 pm - 9:25 pm
Discussion
9:25 pm - 9:30 pm
Closing Remarks
Friday
7:30 am - 8:30 am
Breakfast
9:00 am
Departure
